13Therapeutics, Inc.

13Therapeutics, Inc. is a research and drug development company based in Portland, Oregon, in the United States. It identifies, characterizes, and optimizes novel anti-inflammatory peptide therapeutics aimed at unmet medical needs with high commercial potential. The company is a spin-out from Oregon Health and Science University (OHSU) and holds an exclusive worldwide license to its peptide technology. It performs all in vitro testing in-house and subcontracts animal model testing to OHSU and other academic institutions. The company's therapeutic focus is on inflammatory diseases. Its portfolio of patented anti-inflammatory peptides targets individual intracellular signaling pathways of the Toll-Like Receptor (TLR) pathway. Specific peptides have been identified that block either MyD88-dependent or MyD88-independent TLR signaling. These peptides inhibit the induction of multiple inflammatory mediators such as TNF-alpha and IL-6 and have demonstrated activity both in vitro and in preclinical inflammatory disease models. 13Therapeutics' lead product candidates include peptide P13 and its derivatives, which are inhibitors of multiple TLRs (TLR2, TLR4, and TLR9) and block MyD88-dependent TLR signaling. A second candidate, peptide P7 and its derivatives, inhibits TLR3 and TLR4 and blocks MyD88-independent TLR signaling. The company is exploring applications for these peptides in systemic inflammation, hearing loss, otitis media, and noise-induced hearing loss. 13Therapeutics is privately funded and has received over $10 million in peer-reviewed NIH grants, including multiple Phase I and Phase II SBIR grants. The company's management, board of directors, and scientific advisory board are listed on its website, though specific names are not provided in the available evidence. As a small, privately held biotech, it operates primarily in the United States and is focused on preclinical and early-stage development of its peptide therapeutics.

13Therapeutics, Inc. is a privately held biopharmaceutical company based in Portland, Oregon, United States. It was established as a spin-out from Oregon Health and Science University (OHSU), from which it exclusively licensed its core peptide technology on a worldwide basis. The company's founding year is not specified in the available evidence. The company's scientific foundation rests on the discovery and development of novel anti-inflammatory peptides that target the Toll-Like Receptor (TLR) signaling pathway. These peptides are designed to block specific intracellular signaling cascades—either MyD88-dependent or MyD88-independent—thereby inhibiting the production of multiple inflammatory mediators such as TNF-alpha and IL-6. The company has built a portfolio of patented peptides and has conducted in vitro testing in-house while subcontracting animal model testing to OHSU and other academic institutions. 13Therapeutics has been funded through private investment and has received over $10 million in peer-reviewed grants from the National Institutes of Health (NIH), including multiple Phase I and Phase II SBIR awards. This funding has supported the preclinical development of its lead candidates, P13 and P7, and their derivatives. The company has identified potential applications in systemic inflammation, hearing loss, otitis media, and noise-induced hearing loss. As of the available information, 13Therapeutics remains a small, privately funded preclinical-stage company. It has not announced any clinical trials, partnerships, or regulatory milestones in the provided evidence. Its management team, board of directors, and scientific advisory board are listed on its website, but no individual names are available in the current sources.

Privately funded preclinical-stage biopharmaceutical company developing novel anti-inflammatory peptide therapeutics targeting TLR signaling pathways for unmet medical needs.

• P13

  Peptide P13 and its derivatives are inhibitors of multiple Toll-Like Receptors (TLR2, TLR4, and TLR9) and block MyD88-dependent TLR signaling. They are being developed for inflammatory diseases.

• P7

  Peptide P7 and its derivatives are inhibitors of TLR3 and TLR4 and block MyD88-independent TLR signaling. They are being developed for inflammatory diseases.

1. 1Home13therapeutics.com
2. 2Company13therapeutics.com
3. 3Products13therapeutics.com
4. 413Therapeutics (United States) - Wikidatawikidata.org